These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35413359)

  • 1. Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery.
    Cohen BL; Fleshner P; Kane SV; Herfarth HH; Palekar N; Farraye FA; Leighton JA; Katz JA; Cohen RD; Gerich ME; Cross RK; Higgins PDR; Tinsley A; Glover S; Siegel CA; Bohl JL; Iskandar H; Ji J; Hu L; Sands BE
    Gastroenterology; 2022 Jul; 163(1):204-221. PubMed ID: 35413359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between preoperative tumor necrosis factor alpha inhibitor and surgical site infection after surgery for inflammatory bowel disease: a systematic review and meta-analysis.
    Uchino M; Ikeuchi H; Shimizu J; Ohge H; Haji S; Mizuguchi T; Mohri Y; Yamashita C; Kitagawa Y; Suzuki K; Kobayashi M; Kobayashi M; Sakamoto F; Yoshida M; Mayumi T; Hirata K; Takesue Y
    Surg Today; 2021 Jan; 51(1):32-43. PubMed ID: 32277281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.
    Park KT; Sceats L; Dehghan M; Trickey AW; Wren A; Wong JJ; Bensen R; Limketkai BN; Keyashian K; Kin C
    Aliment Pharmacol Ther; 2018 Aug; 48(3):340-346. PubMed ID: 29876995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
    Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
    South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.
    Law CC; Bell C; Koh D; Bao Y; Jairath V; Narula N
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013256. PubMed ID: 33098570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
    Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
    Lightner AL; Raffals LE; Mathis KL; Cima RR; Tse CS; Pemberton JH; Dozois EJ; Loftus EV
    J Crohns Colitis; 2017 Feb; 11(2):185-190. PubMed ID: 27543504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates.
    Eberhardson M; Myrelid P; Söderling JK; Ekbom A; ; Everhov ÅH; Hedin CRH; Neovius M; Ludvigsson JF; Olén O
    Colorectal Dis; 2022 Apr; 24(4):470-483. PubMed ID: 34905282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and predictors of surgical site infections after bowel resection for Crohn's disease: the role of dual-ring wound protector.
    Ge X; Tang S; Qi W; Liu W; Lv J; Cao Q; Zhou W; Cai X
    Int J Colorectal Dis; 2019 May; 34(5):879-887. PubMed ID: 30868209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumour necrosis factor therapy is associated with de novo Crohn's disease after ileal pouch-anal anastomosis.
    Truong A; Zaghiyan KN; Mirocha J; Melmed GY; McGovern DPB; Syal G; Ha CY; Targan SR; Fleshner PR
    Colorectal Dis; 2021 Sep; 23(9):2416-2424. PubMed ID: 34157179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are Biologics Safe in the Immediate Postoperative Period? A Single-Center Evaluation of Consecutive Crohn's Surgical Patients.
    Lightner AL; Grass F; Alsughayer AM; Harmsen WS; Petersen M; Loftus EV
    Dis Colon Rectum; 2020 Jul; 63(7):934-943. PubMed ID: 32149787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative Serum Vedolizumab Levels Do Not Impact Postoperative Outcomes in Inflammatory Bowel Disease.
    Parrish AB; Lopez NE; Truong A; Zaghiyan K; Melmed GY; McGovern DPB; Ha C; Syal G; Bonthala N; Jain A; Landers CJ; Targan SR; Fleshner P
    Dis Colon Rectum; 2021 Oct; 64(10):1259-1266. PubMed ID: 34516445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients.
    Syed A; Cross RK; Flasar MH
    Am J Gastroenterol; 2013 Apr; 108(4):583-93. PubMed ID: 23481144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis.
    Goodman SM; Menon I; Christos PJ; Smethurst R; Bykerk VP
    Rheumatology (Oxford); 2016 Mar; 55(3):573-82. PubMed ID: 26447162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Postoperative Anti-TNF Therapy Does Not Increase Complications Following Abdominal Surgery in Crohn's Disease.
    Schad CA; Haac BE; Cross RK; Syed A; Lonsako S; Bafford AC
    Dig Dis Sci; 2019 Jul; 64(7):1959-1966. PubMed ID: 30684075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Gu P; Luo J; Kim J; Paul P; Limketkai B; Sauk JS; Park S; Parekh N; Zheng K; Rudrapatna V; Syal G; Ha C; McGovern DP; Melmed GY; Fleshner P; Eisenstein S; Ramamoorthy S; Dulai PS; Boland BS; Grunvald E; Mahadevan U; Ohno-Machado L; Sandborn WJ; Singh S
    Am J Gastroenterol; 2022 Oct; 117(10):1639-1647. PubMed ID: 35973139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis.
    Hanzel J; Almradi A; Istl AC; Yang ML; Fleshner KA; Parker CE; Guizzetti L; Ma C; Singh S; Jairath V
    Dig Dis Sci; 2022 Feb; 67(2):646-660. PubMed ID: 33634430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients.
    Moosvi Z; Duong J; Bechtold ML; Nguyen DL
    Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):799-816. PubMed ID: 33079779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study.
    Lightner AL; Mathis KL; Tse CS; Pemberton JH; Shen B; Kochhar G; Singh A; Dulai PS; Eisenstein S; Sandborn WJ; Parry L; Stringfield S; Hudesman D; Remzi F; Loftus EV
    Inflamm Bowel Dis; 2018 Mar; 24(4):871-876. PubMed ID: 29509927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.